NCT06596876View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations

PHASE3RecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

February 14, 2027

Conditions
Parkinson's Disease
Interventions
DRUG

HRG2010; Sustained-release Carbidopa/Levodopa administered placebo

Subjects will receive HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo administered orally.

DRUG

Sustained-release Carbidopa/Levodopa; HRG2010 placebo

Subjects will receive Sustained-release Carbidopa/Levodopa and HRG2010 placebo administered orally.

Trial Locations (1)

100730

RECRUITING

Beijing Hospital, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY